Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology.
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Figitumumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ADVIGO
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 29 May 2012 Actual patient number changed from 582 to 583 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Planned End Date changed from 1 Jun 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.